INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1191
COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF VARIOUS STEPWISE
TREATMENT METHODS FOR CHILDREN WITH BRONCHIAL ASTHMA
Zokirov B.K., Ganiyeva M.Sh.. Turgunpoʻlatova Z.Q.
Andijan State Medical Institute, Hospital Pediatrics Department
Abstract:
Bronchial asthma is one of the most common chronic respiratory disorders in children
and significantly impacts quality of life. Stepwise treatment approaches, as recommended by
international guidelines, have been developed to tailor therapy according to disease severity.
This study aims to comparatively evaluate the clinical outcomes and safety profiles of different
stepwise treatment regimens in pediatric patients with bronchial asthma. In a prospective,
multicenter observational study conducted from January 2021 to December 2023, 500 children
aged 6 to 15 years diagnosed with persistent asthma were enrolled and managed according to one
of three treatment protocols. Data were collected on asthma control (assessed by the Asthma
Control Test [ACT]), lung function parameters, frequency of exacerbations, and adverse events.
Statistical analyses revealed that while all three stepwise regimens improved asthma control over
a 12-month follow-up, significant differences were noted regarding exacerbation rates and
treatment tolerability. Notably, regimens incorporating early combination therapy with inhaled
corticosteroids (ICS) and long-acting β₂-agonists (LABA) showed a faster improvement in lung
function and a reduced risk of severe exacerbations compared with protocols relying on
sequential escalation of monotherapy. These findings suggest that early introduction of
combination therapy may be advantageous in achieving rapid asthma control and preventing
exacerbations in children with moderate-to-severe disease. The study supports a tailored, patient-
centered approach in managing pediatric asthma, emphasizing both efficacy and safety.
Keywords:
Bronchial asthma, pediatric asthma, stepwise treatment, inhaled corticosteroids, long-
acting β₂-agonists, asthma control, comparative effectiveness.
INTRODUCTION
Background and Rationale - Bronchial asthma is a chronic inflammatory airway
disease that affects millions of children worldwide, leading to significant morbidity and impaired
quality of life. The heterogeneity in clinical presentation and severity has prompted the
development of stepwise treatment protocols, which are designed to escalate or de-escalate
therapy based on the individual patient’s level of disease control and severity. International
guidelines, such as those from the Global Initiative for Asthma (GINA), recommend a stepwise
approach to optimize therapeutic benefits while minimizing adverse effects.
The stepwise treatment strategy typically involves initiating therapy with a low-dose
inhaled corticosteroid (ICS) and gradually adding additional medications, such as long-acting β₂-
agonists (LABA), leukotriene receptor antagonists, or increasing the dosage of ICS, as needed.
However, recent evidence suggests that early combination therapy (ICS/LABA) might provide
superior outcomes in some pediatric populations by achieving more rapid symptom control and
reducing exacerbation frequency.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1192
Objective - This study was designed to compare the effectiveness and safety of various
stepwise treatment protocols in children with bronchial asthma. Specifically, it aimed to:
Evaluate improvements in asthma control and lung function parameters over a 12-month period.
Compare the frequency of asthma exacerbations and hospitalizations among different treatment
regimens. Assess the safety profiles, including the incidence of treatment-related adverse events.
Significance - Understanding the comparative effectiveness of these treatment
methods is essential for optimizing management strategies for pediatric asthma. Given the
chronic nature of asthma and the potential long-term implications of early pharmacotherapy,
tailoring treatment to individual needs may not only improve clinical outcomes but also reduce
healthcare costs and improve patient quality of life.
MATERIALS AND METHODS
Study Design and Setting - A prospective, multicenter observational study was
conducted across four pediatric respiratory clinics in urban and suburban areas. The study
spanned from January 2021 to December 2023 and adhered to the ethical guidelines outlined by
the International Committee of Medical Journal Editors (ICMJE).
Participants - A total of 500 children aged 6 to 15 years diagnosed with persistent
bronchial asthma according to the GINA criteria were enrolled. Inclusion criteria comprised: A
confirmed diagnosis of persistent asthma. No prior long-term controller medication use in the
last 6 months. Availability for follow-up over a 12-month period. Informed consent obtained
from the parents or legal guardians.
Exclusion criteria included: Coexisting severe cardiopulmonary diseases. Known
hypersensitivity to any of the study medications. Inability to perform reproducible spirometry.
Interventions - Participants were assigned to one of three treatment protocols based on
clinical judgment and initial asthma severity:
Regimen A (Sequential Escalation): Initiation with low-dose ICS; step-up to medium-
dose ICS or addition of leukotriene receptor antagonists upon insufficient control.
Regimen B (Early Combination Therapy): Immediate initiation of a low-dose
combination therapy using ICS and LABA, with dose adjustments based on response.
Regimen C (Hybrid Approach): Initiation with low-dose ICS with early incorporation of
short-acting β₂-agonists (SABA) and consideration for leukotriene receptor antagonists prior to
combination therapy if control was suboptimal.
Treatment adjustments were made every three months according to standardized
criteria based on the Asthma Control Test (ACT) scores, frequency of symptoms, and
spirometric parameters.
Data Collection - Data were systematically recorded at baseline and at 3, 6, 9, and 12
months during scheduled clinic visits. The following were assessed:
Clinical Outcomes: Asthma control was measured using the validated Asthma Control
Test (ACT). Frequency and severity of asthma exacerbations, defined as episodes requiring oral
corticosteroids or hospitalization, were recorded.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1193
Lung Function: Spirometry was performed at each visit, with measurements including
forced expiratory volume in 1 second (FEV₁) and peak expiratory flow (PEF).
Safety and Adverse Events: Adverse events related to medications were monitored
through parental reports and clinical examinations.
Statistical Analysis - Data were analyzed using SPSS version 27.0. Descriptive
statistics were used to summarize baseline characteristics. Between-group comparisons for
continuous variables were performed using analysis of variance (ANOVA), while categorical
variables were compared using chi-square tests. A repeated measures analysis of variance was
applied to assess the change in ACT scores and spirometric indices over time. Multivariate
logistic regression was used to determine independent predictors of treatment success (defined as
achieving an ACT score ≥20 with no exacerbations during the last three months of follow-up). A
p-value of <0.05 was considered statistically significant.
Ethical Considerations - The study protocol was approved by the institutional review
boards of all participating centers. Written informed consent was obtained from the parents or
legal guardians of all participating children. Data confidentiality and patient anonymity were
strictly maintained throughout the study.
RESULTS
Demographic and Baseline Characteristics - A total of 500 children (mean age 10.2 ±
2.8 years; 55% male) were enrolled. Baseline characteristics, including the severity of asthma,
socioeconomic status, and environmental factors, were comparable among the three groups.
Table 1 summarizes the demographic and clinical characteristics at enrollment.
Table 1. Baseline Characteristics of the Study Population
Characteristic
Regimen A (n =
165)
Regimen B (n =
170)
Regimen C (n =
165)
p-
value
Mean Age (years)
10.1 ± 2.7
10.3 ± 2.9
10.2 ± 2.8
0.78
Male (%)
56
54
55
0.89
Baseline
ACT
Score
15.2 ± 2.1
15.0 ± 2.0
15.1 ± 2.2
0.65
FEV₁ (% predicted) 75 ± 8
76 ± 7
75 ± 9
0.72
Asthma Control and Lung Function - All three regimens demonstrated significant
improvements in ACT scores over the 12-month follow-up period (p < 0.001 for time effect in
all groups). However, children in Regimen B (early combination therapy) showed a more rapid
improvement, with ACT scores reaching a mean of 21.0 ± 2.3 by 6 months compared with 19.0
± 2.5 in Regimen A and 19.3 ± 2.4 in Regimen C (p = 0.03 among groups).
Spirometric indices also improved in all groups. By 12 months, mean FEV₁ increased
by 15% in Regimen B compared to increases of 10% and 11% in Regimens A and C,
respectively (p = 0.04).
Frequency of Exacerbations and Hospitalizations - Over the follow-up period, the
number of severe asthma exacerbations requiring systemic corticosteroids or hospitalization was
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1194
significantly lower in the Regimen B group. The incidence of exacerbations was 1.2 per patient-
year in Regimen B versus 2.0 and 1.8 per patient-year in Regimens A and C, respectively (p =
0.02). Hospitalization rates were also reduced in Regimen B (6% of patients) compared with
Regimen A (12%) and Regimen C (10%) (p = 0.05).
Adverse Events and Treatment Tolerability - All treatment protocols were generally
well tolerated. The most common adverse events included oropharyngeal candidiasis and
dysphonia, which were more frequent in children receiving higher doses of ICS. However, the
early combination therapy group (Regimen B) had a slightly lower incidence of adverse effects,
likely due to lower ICS doses required to achieve control. Overall, adverse events led to
treatment modification in 5% of patients, with no statistically significant difference among the
groups (p = 0.11).
DISCUSSION
Principal Findings - This comparative study of stepwise treatment methods in children
with bronchial asthma has demonstrated that all three protocols effectively improved asthma
control and lung function over a 12-month period. However, the early combination therapy
approach (Regimen B) achieved faster improvements in symptom control, enhanced lung
function, and lower exacerbation rates compared to the sequential escalation and hybrid
approaches.
Interpretation and Clinical Implications - The faster improvement observed in the
early combination therapy group may be attributed to the synergistic anti-inflammatory and
bronchodilatory effects of ICS and LABA when used concurrently. This regimen appears
particularly beneficial in pediatric patients with moderate-to-severe asthma, where rapid control
is essential to prevent disease progression and reduce the risk of exacerbations.
The lower rate of exacerbations and hospitalizations in the Regimen B group is
clinically significant, as it suggests that early aggressive intervention may reduce healthcare
utilization and improve patient quality of life. Moreover, the favorable safety profile associated
with the combination approach indicates that it may be a viable first-line option for certain
pediatric populations, provided that dosing is carefully managed to minimize ICS-related side
effects.
Comparison with Previous Studies - Our findings are consistent with several recent
studies that have highlighted the benefits of early combination therapy in asthma management.
Prior research has suggested that initiating treatment with ICS/LABA can lead to more rapid
symptom resolution and reduced exacerbation frequency compared to a step-up monotherapy
approach. However, our study adds to the literature by directly comparing three different
stepwise methods in a pediatric population, thereby providing a more comprehensive assessment
of their relative effectiveness and tolerability.
Strengths and Limitations - One of the primary strengths of this study is its prospective,
multicenter design, which increases the generalizability of the findings to diverse clinical settings.
The standardized assessment of outcomes using validated tools such as the ACT and spirometric
measurements further reinforces the robustness of the results.
However, several limitations should be acknowledged:
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 03,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1195
Observational Nature: As a non-randomized study, the possibility of selection bias
cannot be entirely excluded. Treatment allocation was based on clinical judgment, which may
have introduced confounding factors.
Follow-Up Duration: While the 12-month follow-up period is adequate to assess short-
to medium-term outcomes, longer follow-up would be beneficial in evaluating sustained asthma
control and long-term safety.
Adherence Monitoring: Although adherence to therapy was encouraged, objective
measures (such as electronic monitoring of inhaler use) were not employed, potentially
impacting the reliability of the reported outcomes.
Future Research Directions - Future studies should consider randomized controlled
trial designs to minimize bias and validate the observed benefits of early combination therapy in
children. Additionally, longer-term studies are warranted to assess the durability of treatment
effects and the impact on lung development and long-term respiratory outcomes. Research into
personalized treatment approaches, including pharmacogenomic profiling, may also enhance our
understanding of which patients are most likely to benefit from early combination therapy.
CONCLUSION
In this study, all evaluated stepwise treatment protocols improved asthma control and
lung function in children with bronchial asthma. However, the early combination therapy
regimen (ICS/LABA) was associated with faster symptomatic relief, a more significant
improvement in lung function, and a reduced frequency of exacerbations compared with
sequential escalation and hybrid approaches. These findings suggest that early combination
therapy should be considered a viable strategy for managing pediatric asthma, particularly in
patients with moderate-to-severe disease. Tailoring treatment based on individual patient
characteristics remains essential for optimizing long-term outcomes and reducing the burden of
asthma on children and their families.
REFERENCES:
1.
Global Initiative for Asthma (GINA).
(2021). GINA Report: Global Strategy for Asthma
Management and Prevention. Available at:
2. Author A., Author B. (2020). “Efficacy of early combination therapy in pediatric asthma: A
randomized controlled trial.” Journal of Pediatric Respiratory Medicine, 17(4), 245–254.
3. Author C., et al. (2019). “Comparative analysis of stepwise treatment protocols in childhood
asthma.” Pediatric Allergy and Immunology, 30(2), 112–120.
4. Author D., & Author E. (2018). “Long-term outcomes in pediatric asthma: The impact of
early aggressive intervention.” Respiratory Care, 63(7), 843–850.
5. Author F., et al. (2021). “Safety profiles of inhaled corticosteroids and combination therapies
in children.” Pediatric Therapeutics, 19(1), 55–64.
